



## SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110AP1989PLC009713

STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FOR THE YEAR ENDED 31/03/2014

PART - I		<i>Rs. in lakhs</i>				
Sl. No.	PARTICULARS	Quarter ended			Year to date figures	Previous year ended
		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
		Audited	Un-audited	Audited	Audited	Audited
<b>1</b>	<b>Income from operations</b>					
	(a) Net sales/income from operations (Net of excise duty)	13,080.34	11,942.71	7,470.36	51,031.24	25,788.46
	(b) Other operating income	-	-	-	-	-
	<b>Total income from operations (net) (a)+(b)</b>	<b>13,080.34</b>	<b>11,942.71</b>	<b>7,470.36</b>	<b>51,031.24</b>	<b>25,788.46</b>
<b>2</b>	<b>Expenses</b>					
	a) Cost of materials consumed	3,898.42	3,576.20	2,634.47	15,049.65	8,827.40
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	339.57	(1,024.28)	185.25	(1,397.66)	(559.63)
	d) Employee benefits expense	710.62	893.97	554.62	3,144.21	2,537.70
	e) Depreciation and amortisation expense	227.51	224.83	214.43	883.74	786.72
	f) Other expenses - Manufacturing Expenses	1,600.29	1,340.82	1,147.76	5,388.94	3,904.81
	- R & D Expenses	1,238.05	973.08	982.12	4,794.79	3,469.32
	- Others	549.70	694.40	606.92	2,145.45	2,290.30
	<b>Total expenses</b>	<b>8,564.16</b>	<b>6,679.02</b>	<b>6,325.57</b>	<b>30,009.12</b>	<b>21,256.62</b>
<b>3</b>	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>4,516.18</b>	<b>5,263.69</b>	<b>1,144.79</b>	<b>21,022.12</b>	<b>4,531.84</b>
<b>4</b>	<b>Other Income</b>	<b>120.29</b>	<b>84.96</b>	<b>54.29</b>	<b>302.95</b>	<b>104.34</b>
<b>5</b>	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>4,636.47</b>	<b>5,348.65</b>	<b>1,199.08</b>	<b>21,325.07</b>	<b>4,636.18</b>
<b>6</b>	<b>Finance costs</b>	<b>169.51</b>	<b>221.43</b>	<b>270.74</b>	<b>1,051.28</b>	<b>1,350.94</b>
<b>7</b>	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)</b>	<b>4,466.96</b>	<b>5,127.22</b>	<b>928.34</b>	<b>20,273.79</b>	<b>3,285.24</b>
<b>8</b>	<b>Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>9</b>	<b>Profit/Loss from Ordinary Activities before tax (7 + 8)</b>	<b>4,466.96</b>	<b>5,127.22</b>	<b>928.34</b>	<b>20,273.79</b>	<b>3,285.24</b>
<b>10</b>	<b>Tax Expenses</b>	<b>1,226.40</b>	<b>1,483.90</b>	<b>65.30</b>	<b>5,858.04</b>	<b>201.29</b>
<b>11</b>	<b>Net Profit/ (Loss) from Ordinary Activities after tax (9-10)</b>	<b>3,240.56</b>	<b>3,643.32</b>	<b>863.04</b>	<b>14,415.75</b>	<b>3,083.95</b>
<b>12</b>	<b>Extraordinary Items (net of tax expense Rs___)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>13</b>	<b>Net Profit / (Loss) for the period (11 + 12)</b>	<b>3,240.56</b>	<b>3,643.32</b>	<b>863.04</b>	<b>14,415.75</b>	<b>3,083.95</b>
<b>14</b>	<b>Share of profit / (loss) of associates</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>15</b>	<b>Minority interest</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>16</b>	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)</b>	<b>3,240.56</b>	<b>3,643.32</b>	<b>863.04</b>	<b>14,415.75</b>	<b>3,083.95</b>
<b>17</b>	<b>Paid-up equity share capital (Face Value of Rs. 1/- each)</b>	<b>1,168.29</b>	<b>1,168.29</b>	<b>1,168.29</b>	<b>1,168.29</b>	<b>1,168.29</b>
<b>18</b>	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>25,276.34</b>	<b>14,277.70</b>
<b>19.i</b>	<b>Earnings Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):</b>					
	a) Basic	2.77	3.12	0.74	12.34	2.64
	b) Diluted	2.77	3.12	0.74	12.34	2.64
<b>19.ii</b>	<b>Earnings Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):</b>					
	a) Basic	2.77	3.12	0.74	12.34	2.64
	b) Diluted	2.77	3.12	0.74	12.34	2.64

PART - II		31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013
A	PARTICULARS OF SHAREHOLDING	Audited	Un-audited	Audited	Audited	Audited
1	Public share holdings					
	a. Number of shares	41,171,212	41,171,212	41,993,960	41,171,212	41,993,960
	b. Percentage of share holding	35.24%	35.24%	35.94%	35.24%	35.94%
2	<b>Promoters and promoter group Shareholding</b>					
	a) Pledged / Encumbered					
	- Number of shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL
	b) Non-Encumbered					
	- Number of shares	75,657,576	75,657,576	74,834,828	75,657,576	74,834,828
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of shares (as a % of the total share capital of the company)	64.76%	64.76%	64.06%	64.76%	64.06%
Particulars		3 months ended (31/03/2014)				
B	<b>INVESTOR COMPLAINTS</b>					
	Pending at the beginning of the quarter	-				
	Received during the quarter	31				
	Disposed of during the quarter	30				
	Remaining unresolved at the end of the quarter	1				

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED						Rs. in lakhs
PARTICULARS	Quarter ended			Year to date figures	Previous year ended	
	31/03/2014	31/12/2013	31/03/2013	31/03/2014	31/03/2013	
	Audited	Un-audited	Audited	Audited	Audited	
1	<b>SEGMENT REVENUE</b>					
	a) Manufacturing (CRAMS)	12,683.57	11,229.62	6,484.41	49,344.00	24,456.23
	b) Services (DDDSS)	396.78	713.08	985.96	1,687.24	1,332.24
	c) Research & Development	-	-	-	-	-
	<b>Net sales/income from operations</b>	<b>13,080.35</b>	<b>11,942.70</b>	<b>7,470.37</b>	<b>51,031.24</b>	<b>25,788.47</b>
2	<b>SEGMENT RESULTS (Profit/(Loss) before tax and interest)</b>					
	a) Manufacturing (CRAMS)	5,937.20	6,327.79	2,112.34	26,308.56	9,176.71
	b) Services (DDDSS)	200.73	459.14	258.94	888.72	370.00
	c) Research & Development	(1,238.05)	(973.08)	(982.12)	(4,794.79)	(3,469.32)
	<b>TOTAL</b>	<b>4,899.88</b>	<b>5,813.85</b>	<b>1,389.16</b>	<b>22,402.49</b>	<b>6,077.39</b>
	Less: (i) Interest	89.44	117.92	172.97	618.92	1,174.34
	(ii) Other Un-allocable expenses net off	343.47	568.71	287.84	1,509.78	1,617.81
	(iii) un-allocable Income	-	-	-	-	-
	<b>Profit Before Tax</b>	<b>4,466.97</b>	<b>5,127.22</b>	<b>928.35</b>	<b>20,273.79</b>	<b>3,285.24</b>
3	<b>CAPITAL EMPLOYED (Segment Assets - Segment Liabilities)</b>					
	a) Manufacturing (CRAMS)	19,509.25	21,824.86	12,823.28	19,509.25	13,212.39
	b) Services (DDDSS)	3,493.63	3,367.54	3,053.52	3,493.63	3,093.23
	c) Research & Development	1,815.26	2,136.36	2,412.64	1,815.26	2,503.65
	d) Net assets which are not segmented and used commonly	1,626.50	(707.60)	3,574.87	1,626.50	(3,363.29)
	<b>TOTAL</b>	<b>26,444.64</b>	<b>26,621.16</b>	<b>21,864.31</b>	<b>26,444.64</b>	<b>15,445.98</b>

**Notes:**

- The above audited results were approved and taken on record at the Board of Directors' Meeting held on 22nd May, 2014.
- Previous years figures have been regrouped/reclassified whenever necessary.
- The figures of the last quarter are the balancing figures between audited figures in respect of full year and un-audited declared upto 3rd quarter ending.  
The Board has proposed a Dividend of Re. 0.50 per share (50% of face value Rs. 1.00 each), with an additional Special Silver Jubilee year dividend of Rs. 2.00 per share
- (200% of face value of Rs. 1.00 each), aggregating to Rs 2.50 per share for the financial year 2013-14, subject to approval of the shareholders in the ensuing Annual General Meeting.

For SUVEN LIFE SCIENCES LTD

Place : Hyderabad  
Date : 22nd May, 2014

VENKAT JASTI  
Chairman & CEO

*We Deliver*